Predictive Oncology shares are trading higher on Tuesday after the company announced it developed predictive models to target ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Dr. Peter Marks, the FDA's top vaccine official, resigns amid pressure from Health Secretary Robert F. Kennedy Jr., ...

"As we advance our broader strategy to build a leading injectables portfolio with durable, high-impact complex products, we are excited to announce the U.S. launch of Boruzu in our oncology portfolio.

Yet oncology products have a greater likelihood than other therapy areas to fail at Phase III (see graph) – well after the branding process has already begun and market expectations are somewhat ...

Johnson & Johnson JNJ and Pfizer PFE are two of the world’s largest pharmaceutical companies with diversified healthcare ...

with a proven track record of driving revenue growth and expanding market presence for various oncology products. He has held senior positions at major pharmaceutical companies like Bayer ...

The clinical-stage immuno-oncology company said Tuesday that it won't continue to final analysis and cease development of nemvaleukin, its drug that was aimed to treat platinum-resistant ovarian ...

Kanvas Biosciences’ new research suggests that the company’s HiPR-Map Platform is capable of outperforming traditional ...

Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2024 and highlighted recent business progress.

It’s clear the growth rate for oncology products is slowing. Figure 1 Global Oncology Sales and Growth Considering this moderating growth, IMS conducted an Oncology Launch Excellence Study to ...